Literature DB >> 3068750

Bacillus Calmette-Guerin (BCG) endophthalmitis.

H Lester1, R A Erdey, D M Fastenberg, P L Schwartz, J B Rosenhaus.   

Abstract

A patient who had been treated for metastatic bladder carcinoma with bacillus Calmette-Guerin (BCG) vaccine subsequently developed bilateral visual loss secondary to an infiltrative retinitis and vitreitis. Although assumed to have candida endophthalmitis, vitrectomy demonstrated mycobacterium bovis. The patient was placed on systemic anti-tuberculous therapy, and there was noted to be a reduction in retinal lesions prior to his death. This is the first report in the literature documenting endogenous endophthalmitis after BCG usage.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3068750     DOI: 10.1097/00006982-198808030-00006

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  3 in total

1.  Autoimmune retinopathy associated with intravesical BCG therapy.

Authors:  S Sharan; C E Thirkill; J R Grigg
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

2.  Mixed haematogenous endophthalmitis caused by Candida albicans and CDC fermentative corynebacterium group A-4.

Authors:  C Barker; J Leitch; N P Brenwald; M Farrington
Journal:  Br J Ophthalmol       Date:  1990-04       Impact factor: 4.638

Review 3.  Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

Authors:  María Asunción Pérez-Jacoiste Asín; Mario Fernández-Ruiz; Francisco López-Medrano; Carlos Lumbreras; Ángel Tejido; Rafael San Juan; Ana Arrebola-Pajares; Manuel Lizasoain; Santiago Prieto; José María Aguado
Journal:  Medicine (Baltimore)       Date:  2014-10       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.